Angion Biomedica Falls 11% After ANG-3777's Mid-Stage Trial For ARDS Fails

Angion Biomedica Corp. (ANGN) Tuesday evening said that its mid-stage trial of lead candidate ANG-3777 in patients with Covid-19 vaccine related pneumonia at high risk for acute respiratory distress syndrome (ARDS) did not meet the primary or secondary efficacy endpoints.